Clinical trial
Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in…
NCT00420303 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00420303 |
|---|---|
| Title | Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy |
| Official title | A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Spondylarthropathies, Enthesitis |
| Intervention type | Drug, Other |
| Interventions | Etanercept, Placebo |
| Enrollment | 24 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jan 11, 2007 |
| Last update posted | Jul 20, 2010 |
| Countries | France, Germany, Netherlands |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: